Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Avidity Biosciences Inc.
Sponsor

Avidity Biosciences Inc.

United States 3020 Callan Road, 92121-1109, United States

About the sponsor

Avidity Biosciences Inc. funds clinical research in facioscapulohumeral muscular dystrophy, with studies centered on muscle function, mobility, and disease-related weakness in affected adults.

  • Functional mobility
  • Muscle strength
  • Neuromuscular disease

Its clinical activity in this area reflects a focus on therapies for inherited muscle disorders that affect movement and daily physical performance.

About Specializations

Avidity Biosciences Inc. runs clinical trials in conditions such as Facioscapulohumeral muscular dystrophy, Myotonic dystrophy, Duchenne muscular dystrophy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Duchenne muscular dystrophy

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Avidity Biosciences Inc.

Facioscapulohumeral muscular dystrophy

Recruiting
Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Myotonic dystrophy

Recruiting
InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Myotonic dystrophy

Not recruiting
Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Facioscapulohumeral muscular dystrophy

Not recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.